SynopsisElliotts B Solution is indicated as a diluent for the intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma. The global Elliotts B Solution market was valued at US$ .....
SynopsisErwinia L-Asparaginase is an enzyme, as a medication it is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also .....
SynopsisErwinia L-Asparaginase is an enzyme, as a medication it is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also .....
SynopsisErwinase is used in combination with other anti-neoplastic agents to treat acute lymphoblastic leukaemia. It may also be used in other neoplastic conditions where depletion of asparagine might be expected to have a useful effect. The global Erwinase mark.....
SynopsisErwinia L-Asparaginase is an enzyme, as a medication it is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also .....
SynopsisErwinia L-Asparaginase is an enzyme, as a medication it is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also .....
SynopsisImatinib is a medication used to treat cancer. The global Gleevec market was valued at US$ 341 million in 2023 and is anticipated to reach US$ 595.2 million by 2030, witnessing a CAGR of 8.5% during the forecast period 2024-2030. For many patients .....
SynopsisImatinib is a medication used to treat cancer. The global Imatinib Mesylate Drugs market was valued at US$ 341 million in 2023 and is anticipated to reach US$ 595.2 million by 2030, witnessing a CAGR of 8.5% during the forecast period 2024-2030. Fo.....
SynopsisPonatinib Drugs is an oral drug developed by ARIAD Pharmaceuticalsfor the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia(ALL). The global Ponatinib market was valued at US$ 592 million .....
SynopsisPonatinib Drugs is an oral drug developed by ARIAD Pharmaceuticalsfor the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia(ALL). The global Ponatinib Drugs market was valued at US$ 592 mi.....
